Pharmaceuticals, Biotechnology & Life Sciences

Tonix CFO’s June 30 buy of 1,453 shares at $10.91 signals growing insider confidence amid a volatile market, hinting at future upside for investors.

Corcept Therapeutics insider sales show routine portfolio moves, not a shift in strategy – a sign of long‑term confidence for investors.

Arthur Kirsch’s patient 10,000‑share build in EVOMMUNE signals insider confidence amid a weak week—use this insight to gauge long‑term value.

Insider buying at Palisade Bio signals confidence in its rising GI‑therapeutics pipeline, hinting at future upside for investors.

Insider buying spree at Xencor signals executive confidence in upcoming biotech catalysts—investors see bullish potential amid 44% monthly gains.

Insider RSU and option grants by Longeveron’s chief scientist signal long‑term confidence in its aging‑therapy pipeline, offering a bullish hint amid volatile shares.

Investor insight: Dyne Therapeutics insiders sold $1bn in shares—plan‑driven divestiture, not a warning. Learn how this impacts price, liquidity, and future milestones.

Werewolf Therapeutics insider sale: Luke Evnin sells 107,429 shares at $0.32 under a 10b5‑1 plan—minimal market impact but signals caution amid steep stock decline.

Inside PTC Therapeutics: Insider buying/selling patterns reveal long‑term confidence amid short‑term valuation concerns.

CEO Peetz’s modest Mirum buy‑back and small sales reveal routine insider trading, not market shifts—insightful for investors eyeing future growth.